These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 18709988

  • 1. [Comparison of antimicrobial use density (AUD) of carbapenem antibacterial agents and investigation of the drug susceptibility of Pseudomonas aeruginosa in 3 hospitals in southern Ibaraki Prefecture, Japan].
    Oishi T, Hitomi S, Kamoshita M, Fukue H, Kawahata D, Fukutake K.
    Rinsho Byori; 2008 Jul; 56(7):570-6. PubMed ID: 18709988
    [Abstract] [Full Text] [Related]

  • 2. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
    Shigemi A, Matsumoto K, Yaji K, Shimodozono Y, Takeda Y, Miyanohara H, Kawamura H, Orita M, Tokuda K, Nishi J, Yamada K.
    Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
    [Abstract] [Full Text] [Related]

  • 3. The Implementation of a Hospital-wide Practice for the Selective Use of Carbapenems Based on the Monitoring of Susceptibility of Pseudomonas aeruginosa Isolates.
    Ohshima T, Asai S, Miyazawa M, Yamamoto Y, Hisada A, Kumazawa C, Hashimoto M, Fukawa K, Iwashita H, Umezawa K, Yamada S, Yamamoto Y, Miyachi H.
    Tokai J Exp Clin Med; 2017 Dec 20; 42(4):176-181. PubMed ID: 29228415
    [Abstract] [Full Text] [Related]

  • 4. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.
    Sakyo S, Tomita H, Tanimoto K, Fujimoto S, Ike Y.
    J Antibiot (Tokyo); 2006 Apr 20; 59(4):220-8. PubMed ID: 16830889
    [Abstract] [Full Text] [Related]

  • 5. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan.
    Sanbongi Y, Shimizu A, Suzuki T, Nagaso H, Ida T, Maebashi K, Gotoh N.
    Microbiol Immunol; 2009 Jul 20; 53(7):361-7. PubMed ID: 19563394
    [Abstract] [Full Text] [Related]

  • 6. [Comparative antibacterial activity of carbapenems against P. aeruginosa (1)].
    Hikida M, Terashima S, Sato Y, Okamoato R, Inoue M.
    Jpn J Antibiot; 2001 Nov 20; 54(11):571-9. PubMed ID: 11828603
    [Abstract] [Full Text] [Related]

  • 7. The effects of group 1 versus group 2 carbapenems on imipenem-resistant Pseudomonas aeruginosa: an ecological study.
    Carmeli Y, Lidji SK, Shabtai E, Navon-Venezia S, Schwaber MJ.
    Diagn Microbiol Infect Dis; 2011 Jul 20; 70(3):367-72. PubMed ID: 21683268
    [Abstract] [Full Text] [Related]

  • 8. Association of ertapenem and antipseudomonal carbapenem usage and carbapenem resistance in Pseudomonas aeruginosa among 12 hospitals in Queensland, Australia.
    McDougall DA, Morton AP, Playford EG.
    J Antimicrob Chemother; 2013 Feb 20; 68(2):457-60. PubMed ID: 23027714
    [Abstract] [Full Text] [Related]

  • 9. A new carbapenem drug dosage metric for carbapenem usage and correlation with carbapenem resistance of Pseudomonas aeruginosa.
    Hirayama S, Yasui K, Murakami H, Kosugi T, Sakamoto M, Hanai Y, Matsuo K, Miyazaki T, Ishii Y, Nishizawa K, Tateda K.
    J Infect Chemother; 2018 Dec 20; 24(12):949-953. PubMed ID: 30268412
    [Abstract] [Full Text] [Related]

  • 10. [Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from urine at one hospital to mainly carbapenem and fluoroquinolone drugs].
    Watanabe Y, Fujiue Y, Yano S, Shimizu S, Muroki K, Doi M, Kuwabara M.
    Jpn J Antibiot; 2006 Apr 20; 59(2):65-71. PubMed ID: 16805317
    [Abstract] [Full Text] [Related]

  • 11. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ, Nicolau DP.
    J Antimicrob Chemother; 2011 Jun 20; 66(6):1392-5. PubMed ID: 21459897
    [Abstract] [Full Text] [Related]

  • 12. [A comparison of susceptibility of Pseudomonas aeruginosa clinical isolates to carbapenem antibiotics in our hospital].
    Kakeya H, Yamada K, Nakaie K, Takizawa E, Okada Y, Fujita A, Nakamura Y, Abe J, Hirose A, Kaneko Y, Hino M.
    Jpn J Antibiot; 2014 Aug 20; 67(4):241-8. PubMed ID: 25420320
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Absence of association between use of ertapenem and change in antipseudomonal carbapenem susceptibility rates in 25 hospitals.
    Eagye KJ, Nicolau DP.
    Infect Control Hosp Epidemiol; 2010 May 20; 31(5):485-90. PubMed ID: 20334550
    [Abstract] [Full Text] [Related]

  • 15. [Bactericidal activity of biapenem against various bacteria].
    Hiraishi T, Miyata A, Hara T, Araake M, Ogawa H.
    Jpn J Antibiot; 2001 Dec 20; 54(12):581-95. PubMed ID: 11877858
    [Abstract] [Full Text] [Related]

  • 16. [Antibacterial activity of biapenem against recent clinical isolates].
    Hara T, Araake M, Watabe H.
    Jpn J Antibiot; 2003 Apr 20; 56(2):138-41. PubMed ID: 12825414
    [Abstract] [Full Text] [Related]

  • 17. [Study on antibiotics susceptibility and mechanism of carbapenem-resistance in clinical isolates of Pseudomonas aeruginosa].
    Arita K, Daido K, Ohashi N, Nakamura K, Takeshima Y, Kohara T.
    Jpn J Antibiot; 1999 Jul 20; 52(7):491-6. PubMed ID: 10516928
    [Abstract] [Full Text] [Related]

  • 18. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
    Castanheira M, Jones RN, Livermore DM.
    Diagn Microbiol Infect Dis; 2009 Apr 20; 63(4):426-33. PubMed ID: 19249180
    [Abstract] [Full Text] [Related]

  • 19. [Change in antimicrobial susceptibility of Pseudomonas aeruginosa under restricted use of carbapenems].
    Miyazaki H.
    Kansenshogaku Zasshi; 2008 Jan 20; 82(1):6-13. PubMed ID: 18306672
    [Abstract] [Full Text] [Related]

  • 20. A Multicenter Comparison of Carbapenem-Nonsusceptible Enterobacterales and Pseudomonas aeruginosa Rates in the US (2016 to 2020): Facility-Reported Rates versus Rates Based on Updated Clinical Laboratory and Standards Institute Breakpoints.
    Gupta V, Yu KC, Pogue JM, Watts JA, Clancy CJ.
    Microbiol Spectr; 2022 Jun 29; 10(3):e0115822. PubMed ID: 35638777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.